Chinese scientists have discovered potential new targets for the precise treatment of hepatocellular carcinoma

the chinese team of scientists, by measuring the proteomic expression spectrum of early hepatocellular carcinoma and the phosphate protein map, found the potential new target for the precise treatment of hepatocellular carcinoma. In the early hours of February 28th, the journal Nature published the important research online. The research results were carried out by the Institute of Life Group Studies of the Military Medical Research Institute of the Academy of Military Sciences, the Research Team of He Fuchu, a member of the Chinese Academy of Sciences of the National Protein Science Center (Beijing), a team of researcher Qian Xiaohong, a member of the Chinese Academy of Sciences of Sun Yat-sen Hospital affiliated with Fudan University, and a team of Professor Yu Baocai of Peking University Cancer Hospital. Jiang Ying, Sun Aihua, Zhao Yang, Ying Wantao of the Institute of Military Medicine, Sun Huichuan, Yang Xinrong of Zhongshan Hospital affiliated with Fudan University and Yu Bao of Peking University Cancer Hospital are the co-authors of the paper.
According to peer scientists, this is the Ministry of Science and Technology in 2014 to launch the "class Chinese proteomics program", the National Protein Science Center (Beijing) Chief Scientist He Fuchu in the journal Nature published the second landmark results. The researchers believe that this major breakthrough in the field of hepatocellular carcinoma proteomics has a wide range of social applications, known as the "Chinese proteomics program" ushered in the first dawn.
The researchers reviewed that based on proteomic data from 101 samples of tissue next to early hepatocellular carcinoma and matching cancer, they divided the current clinically considered early hepatocellular carcinoma patients into three proteomic subsypes, while patients with different subsypes had different prognostic characteristics and needed different treatment options after surgery. Among them, the first category of patients only need surgery to prevent overtreated, the second category of patients need surgery plus other complementary treatment, while the third category of patients accounted for 30%, after surgery, the risk factor of recurrence and metastasis is the largest, is the last "hard bone." They found that in proteomic data from the third group of patients, the cholesterol metabolic path pathline was reprogrammed, in which the high expression of the candidate target cholesterol esterase (SOAT1) had the worst prognosis risk, and by inhibiting SOAT1, cholesterol levels on the cytocyte membrane were reduced, effectively inhibiting the proliferation and migration of tumor cells.
further studies, they found that Avamabu, a small molecular inhibitor of SOAT1, showed good anti-tumor effects on the human-sourced tumor heterogeneous transplant model in liver cancer patients. This bodes well for the potential target treatment of patients with poor prognosis for hepatocellular carcinoma.
first time that a direct link between cholesterol metabolic pathway reprogramming and hepatocellular carcinoma confirmed the importance of cholesterol esterase in liver cancer. At the same time, with the help of patient group proteomics data analysis, it is also found that cholesterol esterase can be used for early liver cancer type, prognosis and targeted treatment, its protein level in head and neck cancer, stomach cancer, prostate cancer, kidney cancer and thyroid cancer, are related to the patient's poor prognosis, thus providing an important basis for the development of new anti-cancer drugs.
It is learned that the National Protein Science Center (Beijing), also known as the "Phoenix Center", has the world's largest high-end proteomic sequencing platform and "Tianhe 2" architecture supercomputer as the representative of the world's top hardware facilities. Proteomics, functional proteomics, translational medicine, bioinficion, drug metabolism research and development, gene therapy and diagnostic reagents and other six technology platforms and experimental animals, biological resources and other support platforms, the total value of equipment nearly 400 million yuan.
"Phoenix Center" established the world's fastest proteomics identification method, the creation of the world's first proteomics one-stop data analysis system, proteomics research field to achieve "hardware and software" double leadership. Lead the implementation of Chinese proteomics program focus on special projects, leading more than 60 units in China to collaborate on human proteomics research, and promote the further development of proteomics research in China. (Source: Science Network Wang Jing)
relevant paper information: